Regadenoson

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

Royalty Pharma Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 8, 2023
Novartis, Aplastic anemia, Vertex, Food, N/A, Pressure, PFS, Cabozantinib, Schizophrenia, New Drug Application, Clinical trial, OS, Calendar, Sale, Exelixis, GAAP, Acquisition, Civil service commission, Apalutamide, Roche, NDA, Papillary tumors of the pineal region, Therapy, Patient, Food and Drug Administration, KarXT, European Commission, Risdiplam, Growth, Cystic fibrosis, Growth hormone, Ipsen, FDA, Progression-free survival, EBITDA, Bladder cancer, Ferring Pharmaceuticals, PTC, Multiple sclerosis, Carcinoma, PTC Therapeutics, Pharmaceutical industry, Video game, Music, Bank, Generic drug, Cryptocurrency, Adjustment, Lonapegsomatropin, Ibrutinib, Regadenoson, Cytokinetics, Nadofaragene firadenovec, Nusinersen, Elexacaftor/tezacaftor/ivacaftor

Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired the Spinraza royalty in the first quarter of 2023.
  • In September 2023, Royalty Pharma acquired a royalty interest in Skytrofa from Ascendis Pharma A/S ( press release ) for an upfront payment of $150 million.
  • During the third quarter of 2023, Royalty Pharma repurchased approximately five million shares for $144 million.

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Retrieved on: 
Friday, May 5, 2023
FDA, Pharmaceutical, Health, Cardiology, USFDA, NSE, BSE, Astellas Pharma, Laboratory, Food and Drug Administration, RDY, Regadenoson, NYSE, Generic drug

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).
  • Dr. Reddy’s Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).
  • Please click here to see the full prescribing information: https://www.drreddys.com/pi/150092149-REGADENOSON-Leaflet.pdf
    Lexiscan® is a registered trademark of Astellas US LLC.

GE Healthcare’s Stress Agent Rapiscan (Regadenoson) Approved for use in Stress Cardiac Magnetic Resonance Imaging

Retrieved on: 
Monday, February 14, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Cardiology, Magnetic resonance, Instagram, Ecosystem, EMA, NYSE, Patient, PET, Positron emission tomography, Insight, European Medicines Agency, ESC, MRI, Radiology, GE Healthcare, CAD, Thomas Edison, Product, Adult, Coronary artery disease, Regadenoson, SPECT, University of Milan, European Society of Cardiology, Gold, Cardiology, LinkedIn, Twitter, CMR, Laboratory, Echocardiography, Diagnosis, University, News, Meta-analysis, Exercise, Magnetic resonance imaging, CT scan, Heart, Medical imaging, Medical device, Rapiscan, Facebook

GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent Rapiscan (Regadenoson).

Key Points: 
  • GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent Rapiscan (Regadenoson).
  • Dr Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan said: Our experience with Rapiscan in stress MR was very positive.
  • GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT and nuclear medicine imaging.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).